{"schema_version":"secwatch.filing_event.v1","accession":"0000318154-25-000070","form_type":"8-K","ticker":"AMGN","cik":"0000318154","company_name":"AMGEN INC","filed_at":"2025-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.704146+00:00","generated_at":"2026-05-17T00:45:17.229358+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Amgen Q3 revenue up 12% to $9.6B, GAAP EPS $5.93, non-GAAP EPS $5.64","bullets":["Revenue $9.6B (+12% YoY), product sales growth 12% on 14% volume growth, partially offset by 4% lower net price.","GAAP EPS $5.93 (+14% YoY), includes $400M Otezla intangible asset impairment charge.","Non-GAAP EPS $5.64 (+1% YoY); non-GAAP operating margin 47.1%, down 2.5 ppt.","Free cash flow $4.2B vs $3.3B in Q3 2024, driven by working capital timing and lower interest.","Sixteen products delivered double-digit sales growth including Repatha, EVENITY, TEZSPIRE, and BLINCYTO."],"urls":{"canonical":"https://secwatch.observer/filing/0000318154-25-000070","json":"https://secwatch.observer/filing/0000318154-25-000070.json","markdown":"https://secwatch.observer/filing/0000318154-25-000070.md","text":"https://secwatch.observer/filing/0000318154-25-000070.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/318154/000031815425000070/0000318154-25-000070-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/318154/000031815425000070/amgn-20251104.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:45:17.229358+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}